Great Neck, NY and Plantation, FL - Neogenix Oncology, Inc.
(Neogenix) and Goodwin Biotechnology Inc. (GBI) announced that they have entered into an agreement for process development and manufacturing of Neogenix's first therapeutic product, NPC-1C, a novel monoclonal antibody intended for the treatment of advanced pancreatic cancer. On successful completion of this phase of development, and with FDA approval, Neogenix will begin Phase I and Phase II trials of the product, which are currently planned for the first half of 2008.
Neogenix is a cancer therapeutics and diagnostic company focused on developing
innovative new products for the management of serious and difficult to treat
cancers. The company's portfolio includes monoclonal antibodies that recognize
cancer-specific immunogenic proteins (tumor-associated antigens) derived from
specific tumor systems. Neogenix monoclonal antibodies are of value in that they
define the immunogenic tumor protein as both a diagnostic marker and as a
therapeutic target for tumor destruction.
NPC-1C is the first of these products to enter development, and was derived from
cancer vaccines that demonstrated effective anti-tumor activity and safety in Phase
I-III clinical trials in the 1970-80s. Anti-tumor activity has been shown in in-vitro
ADCC assays and in recently completed animal studies.
An Important Step
"Entering this next phase of development with NPC-1C represents an important
milestone for our company," said Myron Arlen, MD, Neogenix CEO and Founder.
"We look forward to working closely with GBI to produce a high quality antibody
that will allow us to enter Phase I and II trials as soon as possible."
"We strive to partner fully with our clients," commented Stephanie Finnegan, CEO
of GBI. "Our founding mission, fifteen years ago, was to assist companies in
moving products from the research bench into and through human clinical trials.
While it is always gratifying to help in this way, it is especially rewarding to assist
companies such as Neogenix with treatments for non-recourse diseases such as
pancreatic cancer, an especially insidious killer."
SOURCE: Neogenix Oncology, Inc. and Goodwin Biotechnology